Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD

10.66  +0.16 (+1.52%)

After market: 10.66 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALVO. ALVO was compared to 558 industry peers in the Biotechnology industry. ALVO has a medium profitability rating, but doesn't score so well on its financial health evaluation. ALVO is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ALVO has reported negative net income.
ALVO had a negative operating cash flow in the past year.
In the past 5 years ALVO always reported negative net income.
ALVO had a negative operating cash flow in each of the past 5 years.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

ALVO has a Return On Assets of 7.75%. This is amongst the best in the industry. ALVO outperforms 93.91% of its industry peers.
ALVO's Return On Invested Capital of 10.37% is amongst the best of the industry. ALVO outperforms 95.52% of its industry peers.
Industry RankSector Rank
ROA 7.75%
ROE N/A
ROIC 10.37%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

ALVO's Profit Margin of 16.42% is amongst the best of the industry. ALVO outperforms 94.62% of its industry peers.
With an excellent Operating Margin value of 21.88%, ALVO belongs to the best of the industry, outperforming 96.06% of the companies in the same industry.
The Gross Margin of ALVO (60.74%) is better than 79.03% of its industry peers.
Industry RankSector Rank
OM 21.88%
PM (TTM) 16.42%
GM 60.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

ALVO has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ALVO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ALVO has been reduced compared to a year ago.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.37, we must say that ALVO is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.37, ALVO is doing good in the industry, outperforming 62.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.37
ROIC/WACC1.24
WACC8.4%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 1.73 indicates that ALVO should not have too much problems paying its short term obligations.
ALVO has a Current ratio of 1.73. This is in the lower half of the industry: ALVO underperforms 79.75% of its industry peers.
A Quick Ratio of 1.19 indicates that ALVO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.19, ALVO is doing worse than 85.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.19
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

ALVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.39%, which is quite impressive.
ALVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 426.84%.
Measured over the past years, ALVO shows a very strong growth in Revenue. The Revenue has been growing by 42.86% on average per year.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

ALVO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.00% yearly.
The Revenue is expected to grow by 42.98% on average over the next years. This is a very strong growth
EPS Next Y104.4%
EPS Next 2Y55.38%
EPS Next 3Y41%
EPS Next 5YN/A
Revenue Next Year29.67%
Revenue Next 2Y43.31%
Revenue Next 3Y42.98%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVO. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 29.58, which means the current valuation is very expensive for ALVO.
ALVO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALVO is cheaper than 90.68% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.06. ALVO is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 29.58
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALVO is valued cheaply inside the industry as 93.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.09
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALVO's earnings are expected to grow with 41.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.38%
EPS Next 3Y41%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (6/6/2025, 5:20:00 PM)

After market: 10.66 0 (0%)

10.66

+0.16 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-14 2025-08-14/amc
Inst Owners5.83%
Inst Owner ChangeN/A
Ins Owners0.61%
Ins Owner ChangeN/A
Market Cap3.22B
Analysts78
Price Target18.36 (72.23%)
Short Float %0.82%
Short Ratio4.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)225.45%
Min EPS beat(2)38.96%
Max EPS beat(2)411.94%
EPS beat(4)4
Avg EPS beat(4)2391.55%
Min EPS beat(4)38.96%
Max EPS beat(4)9050.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)33.69%
Min Revenue beat(2)30.36%
Max Revenue beat(2)37.03%
Revenue beat(4)3
Avg Revenue beat(4)19.69%
Min Revenue beat(4)-2.08%
Max Revenue beat(4)37.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-372.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-84.88%
Revenue NQ rev (1m)-6.05%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-8.78%
Revenue NY rev (3m)-8.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.58
P/S 5.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 27.09
EPS(TTM)-0.87
EYN/A
EPS(NY)0.36
Fwd EY3.38%
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS1.95
BVpS-1
TBVpS-1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.75%
ROE N/A
ROCE 13.13%
ROIC 10.37%
ROICexc 10.8%
ROICexgc 11.19%
OM 21.88%
PM (TTM) 16.42%
GM 60.74%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 7.35
Cap/Depr 234.04%
Cap/Sales 12.89%
Interest Coverage 2.32
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.19
Altman-Z -0.37
F-Score6
WACC8.4%
ROIC/WACC1.24
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y104.4%
EPS Next 2Y55.38%
EPS Next 3Y41%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year29.67%
Revenue Next 2Y43.31%
Revenue Next 3Y42.98%
Revenue Next 5YN/A
EBIT growth 1Y141.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year175.98%
EBIT Next 3Y87.82%
EBIT Next 5YN/A
FCF growth 1Y45.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.75%
OCF growth 3YN/A
OCF growth 5YN/A